Arena (ARNA), Eisai win FDA approval for diet pill lorcaserin
Tweet Send to a Friend
Up)
Arena (Nasdaq: ARNA), Eisai win FDA approval for diet pill lorcaserin.
The companies must conduct 6 post-marketing studies.
With approval, Arena Pharmaceuticals' lorcaserin (Belviq) becomes first weight-loss drug approved in 13 years.
Shares are currently halted.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The companies must conduct 6 post-marketing studies.
With approval, Arena Pharmaceuticals' lorcaserin (Belviq) becomes first weight-loss drug approved in 13 years.
Shares are currently halted.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Oncolytics Biotech (ONCY) REOLYSIN w/ REO 020 Met Primary Endpoint in Phase 2
- Rigel Pharma (RIGL) Advances R348 to Phase 2
- Ford Motor (F) Will Ramp Production, Halves Two-Week Plant Idling
Create E-mail Alert Related Categories
Corporate News, FDA, Hot Corp. News, Hot FDA News, Hot List
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
